<DOC>
	<DOC>NCT01298531</DOC>
	<brief_summary>This study will compare the Non Steroidal Anti-Inflammatory Drugs (NSAIDs) sparing effect of etanercept with that of placebo in adult subjects with axial Spondyloarthritis.</brief_summary>
	<brief_title>A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Male and female subjects aged 18 years and over at the time of consent to the study. Diagnosis of SpA, as defined by the ASAS criteria for axial SpA Axial involvement refractory to previous or current intake of NSAIDs, defined as at least 2 NSAIDs at maximum tolerated dose determined from past medical history taken for a duration of &gt; 1 month (for both NSAIDs combined) before the Screening visit. Active axial involvement defined by mini BASDAI Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial. Subjects who have received any previous treatment with etanercept or other TNFÎ± inhibitors or biologic agents. Subjects with a known or expected allergy, contraindication, or hypersensitivity to etanercept or its excipients.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Etanercept</keyword>
	<keyword>Axial Spondyloarthritis</keyword>
	<keyword>NSAIDs sparing effect</keyword>
</DOC>